Skip to main content

4 Repeat Tauopathy Neuroimaging Initiative

Active, not recruiting

The purpose of this study is to identify the best methods for tracking and analyzing progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) over time. Researchers will evaluate several different tests, including brain imaging, eye movement, body fluid samples, measurements of memory and other thinking abilities, and measures of functional independence, in the hope that this information can be used to guide diagnosis and treatment of PSP and CBD in the future.

Minimum Age Maximum Age Gender Healthy Volunteers
45 Years 90 Years Both No
January 2011
August 2016

  • Clinical diagnosis of PSP or CBD
  • Reliable study partner who has frequent contact with participant

  • Significant neurological disease other than PSP or CBD
  • Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments, or foreign objects in the eyes, skin. or body

In this observational study, investigators will use several different tests to identify which ones are most useful for tracking and analyzing PSP and CBD, two serious neurological diseases. Tests to be evaluated include brain imaging, eye movement, blood and cerebrospinal fluid samples, measurements of memory and other thinking abilities, and measures of functional independence. The long-term goal is to develop biomarkers that can provide precise, direct measures of the state of the brain, which will help improve clinical trials and, ultimately, treatment for these disorders.

Name City State Zip Status Primary Contact
University of California, San Francisco
San Francisco California 94158

University of California, San Francisco

  • National Institutes of Health (NIH)
  • National Institute on Aging (NIA)

Name Role Affiliation
Adam L. Boxer, MD, PhD Principal Investigator University of California, San Francisco

Name Phone Email
Lisa B. Voltarelli 415-476-9578


Observational Longitudinal Study of Magnetic Resonance Imaging, Specimen Biomarkers, and Clinical Progression in Progressive Supranuclear Palsy and Corticobasal Degeneration